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Abstract
Background: Little is known about the relationship between preoperative body mass index and need for adjuvant
radiation therapy (RT) following radical prostatectomy. The goal of this study was to evaluate the utility of body
mass index in predicting adverse clinical outcomes which require adjuvant RT among men with organ-confined
prostate cancer (PCa).
Methods: We used a prospective cohort of 1,170 low-intermediate PCa risk men who underwent radical
prostatectomy and evaluated the effect of body mass index on adverse pathologic features and freedom from
biochemical failure (FFbF). Clinical and pathologic variables were compared across the body mass index groups
using an analysis of variance model for continuous variables or χ2 for categorical variables. Factors related to
adverse pathologic features were examined using logistic regression models. Time to biochemical recurrence was
compared across the groups using a log-rank survivorship analysis. Multivariable analysis predicting biochemical
recurrence was conducted with a Cox proportional hazards model.
Results: Patients with elevated body mass index (defined as body mass index ≥25 kg/m2) had greater
extraprostatic extension (p = 0.004), and positive surgical margins (p = 0.01). Elevated body mass index did not
correlate with preoperative risk groupings (p = 0.94). However, when compared with non-obese patients (body
mass index <30 kg/m2), obese patients (body mass index ≥30 kg/m2) were much more likely to have higher rate of
adverse pathologic features (p = 0.006). In patients with low- and intermediate- risk disease, obesity was strongly
associated with rate of pathologic upgrading of tumors (p = 0.01 and p = 0.02), respectively. After controlling for
known preoperative risk factors, body mass index was independently associated with ≥2 adverse pathologic
features (p = 0.002), an indicator for adjuvant RT as well as FFbF (p = 0.001).
Conclusions: Body mass index of ≥30 kg/m2 is independently associated with adverse pathologic features, which
is an indicator for additional RT, particularly in patients with low-intermediate risk disease. Future studies may
determine if this select group of patients may be best treated with definitive RT to reduce toxicity from additional
RT following radical prostatectomy. We propose including body mass index in clinical decision-making for
appropriate treatment recommendation for patients with low-intermediate risk PCa.
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Background
Obesity, one of the most pressing issues facing the U.S.
healthcare system, is a potentially modifiable risk factor
for disease progression and poor outcomes for numer-
ous diseases, including prostate cancer (PCa) [1]. Specif-
ically, associations between increased body mass index
(BMI) and advanced prostate tumor stage and grade at
diagnosis, younger age at diagnosis, and biochemical fail-
ure (FFbF, disease recurrence) after treatment have been
observed. [2–4] While investigators study the underlying
mechanisms that link obesity to poor PCa outcomes
[5–8], understanding how BMI may influence treat-
ment recommendations is a critical aspect of ongoing
PCa care.
The current guidelines for patients with organ-confined
PCa include definitive modalities such as radical prosta-
tectomy (RP) or radiation therapy (RT) [9–12]. RP is a
standard surgical management for clinically localized PCa
in patients free of surgical contraindications. This proced-
ure confers excellent 10-year long-term disease control of
>90 % in patients who are confirmed pathologically to
have localized (pT2) disease. Retrospective studies re-
ported that the long-term outcomes of patients with local-
ized and low-risk PCa were equally favorable with RP or
external beam radiation therapy [13, 14]. For intermediate
and high risk disease, however, monotherapy with either
RP or RT did not achieve the excellent long-term out-
comes seen in patients with low-risk disease [15, 16]. For
pT3 cancer (defined as disease in the extraprostatic exten-
sion or seminal vesicle involvement), the risk of 5-year
local failure and biochemical progression varies from 20 %
to 70 % [17, 18]. Several randomized studies for patients
with pT3 (with or without positive margin) or pT2 (with
positive surgical margin) disease have been reported, dem-
onstrating that adjuvant RT reduces the risk of local re-
lapse and biochemical progression and disease-specific
survival [19–22]. Despite earlier cancer detection with ser-
umPSA screening, approximately 50 % of patients who
undergo RP are found to have at least one adverse patho-
logic feature(APF), including advanced tumor grade/stage
and positive margins/lymph nodes, extraprostatic exten-
sion and seminal vesicle invasion [23]. These patients may
require adjuvant RT.
Several studies have shown increased genitourinary
and gastrointestinal toxicity from additional RT after RP
[22, 24–26]. In the South West Oncology Group trial,
adverse events were more likely to occur in the RP + RT
arm compared with the RP arm (23.8 % vs 11.9 %), in-
cluding urethral strictures (17.8 % vs 9.5 %), total urinary
incontinence (6.5 % vs 2.8 %), and rectal complications
(3.3 % vs 0 %), respectively [25]. A study on the health-
related quality of life (HRQOL) of PCa patients com-
pared short- and long-term effects of adjuvant treatment
versus observation after RP [26]. The investigators
reported that the addition of RT to RP resulted in more
frequent urination, as well as early report of more bowel
dysfunction. Another HRQOL in patients treated with
multimodality for PCa reported a decline in HRQOL
particularly with urinary function, urinary bother and
sexual function [24]. Therefore, the ability to preopera-
tively identify the subset of patients who are at risk of
requiring additional RT after RP will be of clinical utility.
These patients may benefit from upfront definitive RT
to improve quality of life and minimize additional tox-
icity from a combination of RP followed by RT. To date
the most widely utilized predictors of clinical outcomes
including PSA, Gleason score (GS) and clinical stage are
sub-optimal in predicting adverse pathologic outcomes
and adjuvant RT use following RP. Over the last decade,
a large body of evidence has emerged associating obesity
with incidence of PCa [27–29] as well as adverse out-
comes following treatment. Recent studies found in-
creased BMI to be associated with aggressive PCa and
FFbF [30–34]. However, no studies have examined the
relationship between preoperative BMI and the need for
adjuvant RT following RP in patients with adverse
pathologic outcomes. We sought to determine whether
BMI provides a clinically useful prediction of adverse
pathologic outcomes that will guide physicians in
recommending RT for select patients with organ-
confined PCa. Obesity, in particular, has been related to
a number of factors and molecular pathways that may
advance cancer progression [35]. We hypothesize that
obesity status modifies the relationship between preclin-
ical risk and PCa outcomes among low-intermediate risk
patients. The study aims were to utilize a cohort of rad-
ical prostatectomy patients to 1) examine the relation-
ship between obesity and adverse pathology, and 2)
examine the relationship between obesity and FFBF.
Methods
Patient population
This study utilizes a cohort of 1970 men with PCa
treated with RP and bilateral pelvic lymph node dissec-
tion at the Hospital of the University of Pennsylvania
Health System (UPHS; Philadelphia, PA.) Patients were
consented in person and recruited at UPHS to partici-
pate in a PCa study, the Study of Clinical Outcomes,
Risk and Ethnicity (SCORE) between 1990 and 2012 as
previously described [36, 37]. This study was approved
by the Institutional Review Board at the University of
Pennsylvania.
The SCORE study includes information on patient
age, race, height, weight, clinical stage, clinical Gleason
on diagnostic biopsy, preoperative PSA levels, surgical
pathologic information (tumor grade, stage, surgical
margins status, extraprostatic extension, or seminal
vesicle involvement, lymph node status). Prospective
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follow -up was conducted with PSA levels obtained at
each visit. For the purpose of this study, patients without
height and weight data for BMI calculation were ex-
cluded from the analysis (N = 506). Patients without ad-
equate preclinical data including initial PSA (N = 30), or
biopsy Gleason (N = 264) at diagnosis were excluded
from the analysis. Patients who received androgen
deprivation therapy (ADT) or adjuvant RT and/or ADT
were included. The remaining 1170 patients were ana-
lyzed in this study.
Data collection
The standard protocol for men in the SCORE study was
as follows: Patients were evaluated at time of diagnosis
by a thorough history and physical examination (includ-
ing digital rectal examination [DRE]) followed by routine
laboratory studies, including serum PSA levels, and GS
determined by needle biopsy and reviewed at the UPHS.
The patients were examined 1 month postoperatively and
then at 3 month intervals for 1 year, every 6 months for
5 years, and then annually. At each follow up visit a
complete evaluation, including DRE and serial PSA values,
were determined and recorded. Biochemical recurrence
(PSA failure) was defined as a single PSA ≥0.2 ng/ml or
when two consecutive PSA values of 0.2 ng/ml were ob-
tained after an undetectable value. Time zero (the starting
point for follow-up) was defined at the date of surgery for
all patients. If PSA was never undetectable postopera-
tively, then PSA failure was assigned at time zero. Patients
with no follow up data were included for the evaluation of
differences in preoperative and pathologic characteristics,
but not biochemical recurrence.
Data related to patient and clinical characteristics,
tumor pathology, and PCa outcomes were collected via
medical record abstraction. All patients were staged
according to the 1992 American Joint Committee on
Cancer staging system [38].
Treatment
Surgical treatment consisted of a radical retropubic
prostatectomy and bilateral pelvic lymph node sampling
or robotic-assisted laparoscopic prostatectomy. Adverse
pathologic features (APF), such as extraprostatic exten-
sion (EPE), seminal vesicle invasion (SVI), and surgical
margin status (SM), were noted and recorded. At the
discretion of the treating physician, patients with APF
including EPE, SVI or positive surgical margins were
treated with adjuvant RT and/or ADT. ADT consisted of
a gonadotropin-releasing hormone agonist (leuprolide
acetate or goserelin acetate) with or without antiandro-
gens (flutamide). The SCORE study is a prospectively
maintained database with patients treated from the
1990s until 2012. For this reason the year of prostatec-
tomy was recorded and introduced into our modeling to
account for difference in pre-PSA era of diagnosis and
improvements in surgical treatment techniques that may
impact APFs.
Risk classification
Preoperatively patients were stratified into low, inter-
mediate and high risk groups according to the recent
National Comprehensive Cancer Network (NCCN)
guidelines [39]. Patients who had T1 to T2a tumors, and
a Gleason score < 7, and a PSA level < 10 ng/mL were
classified as low risk (N = 777); patients who had T2b to
T2c tumors, and/or a Gleason score of 7, and/or a PSA
level between 10 ng/mL and 20 ng/mL were classified as
intermediate risk (N = 270); and patients who had > T3
tumors, or a Gleason score between 8 and 10, or a PSA
level > 20 ng/mL were classified as high risk (N = 117)
[38]. Following RP patients were further stratified by the
number of APFs into low, intermediate and high RPrisk
groups. Patients with no APFs were in the low RPrisk
(N = 818); patients with only 1 APF were in the inter-
mediate RPrisk (N = 177); and patients with >/=2 APFs
were in the high RPrisk group (N = 175).
Statistical analysis
BMI
For the purpose of this study BMI (weight in kilograms
divided by height in meters squared) was categorized as
follows; normal weight (<25 kg/m2), overweight (≥25 kg/m2
to <30 kg/m2), obese (≥30 kg/m2). BMI was examined
as a continuous and a categorical variable in which case
BMI was stratified into non-obese (<30 kg/m2) or obese
(≥30 kg/m2).
Other patient/clinical variables
Age, PSA, year of surgery, and biopsy Gleason score
were examined as continuous variables. Clinical T-stage
(T1c, T2a, T2b, and T2c) and race (white, African-
American/black, and other) were examined as categorical
variables.
Clinical and pathologic variables were compared
across the BMI groups using an analysis of variance
model for continuous variables or χ2 for categorical vari-
ables. Factors associated with the presence of APF were
examined using logistic regression models. The predict-
ability of BMI was evaluated using more stringent cri-
teria of ≥2 APF in order to rigorously select for the
patients that are most likely to be offered additional RT.
For Cox proportional hazards models predicting FFbF,
patients who experienced biochemical recurrence or
PSA failure, lost to follow up, deceased were censored.
Treatment outcomes often correlate with biochemical
control rates thus, a PSA rise to 0.2 ng/ml was used to
define biochemical disease recurrence, and time to
biochemical recurrence was used as a surrogate for
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biochemical disease-free survival. Time to biochemical
recurrence was compared across the groups using a log-
rank survivorship analysis. For both univariate and
multivariate analyses, BMI, Race, clinical stage, and clin-
ical Gleason score were evaluated as categorical variables
as follows: BMI categorical used BMI <25 kg/m2 as ref-
erence category; Race used White as reference category;
“Other” race was dropped from model due to small
numbers. Clinical stage categorical (T1; T2a, T2b; >T2c),
used T1c as reference category; clinical Gleason score
categorical (6, 7, ≥8) used Gleason 6 as reference cat-
egory. The analyses were conducted using STATA
statistical software version 13.0 (STATA Corporation).
A p-value <0.05 was considered statistically significant.
Results
The patient clinical and pathologic characteristics are
listed in Table 1. Preoperative factors such as age, PSA
at diagnosis, biopsy Gleason, clinical T-stage and year of
RP were similar between BMI categories except for race,
where African American/Black race was associated with
elevated BMI (p < 0.001). There was a statistically signifi-
cant difference between postoperative pathologic features
and BMI. Specifically, extraprostatic extension, p = 0.001;
positive surgical margins, p = 0.01; and higher pathologic
Gleason (p = 0.001).
As shown in Table 2, BMI was not associated with
preoperative risk groupings (p = 0.94). However, obesity
(BMI ≥30 kg/m2) directly correlated with increased risk
of APFs (; p = 0.006). The effect of BMI and outcomes
by pre-operative risk grouping was evaluated as per the
National Comprehensive Cancer Network classification.
Obesity (BMI ≥30 kg/m2) was strongly associated with a
higher rate of pathologic Gleason score upgrading of
tumors, particularly for low risk (Fig. 1a-b, 30 % vs.
Table 1 Pre- and post- treatment characteristics and pathologic
outcomes of men undergoing radical prostatectomy at
University of Pennsylvania, 1990–2012
Body mass index (kg/m2) p-value
<25 % 25–30 % >30 %
iPSA (ng/ml) 0.95b
median 5.1 5.4 5.2
mean 6.59 6.73 6.76
IQR 3.9–6.8 4.2–7.2 4.1–7.2
Age (years) 0.37b
median 60 60 59
mean 59.1 59.2 58.6
IQR 54–64 54–64 54–63
Biopsy Gleason Score 0.46a
≤ 6 150 82 459 76 293 77
7 25 14 102 17 61 16
8 to 10 7 4 40 7 73 6
Clinical T-stage 0.99a
T1c 121 80 392 81 251 80
T2a 24 16 73 15 51 16
T2b 3 2 9 2 6 2
T2c 3 2 12 2 5 2
Race <0.001a
white 149 83 487 82 270 71
African-American/Black 31 17 106 18 112 29
other 4 2 9 2 2 0.5
Pathologic Gleason Score 0.001a
≤ 6 106 58 321 53 165 43
7 71 39 252 42 186 48
8 to 10 7 4 29 5 33 9
Nodal Status 0.47a
pN0 184 100 592 99 379 99
pN1 0 0 3 1 3 1
Extraprostatic spread 39 21 130 22 117 30 0.004a
Seminal Vesicle invasion 9 5 29 5 26 7 0.39a
Positive surgical margin 19 10 108 18 78 21 0.01a
Additional
Radiotherapy
1 0.6 11 2 8 2 0.39a
Hormonal Therapy 7 4 30 5 16 4 0.51a
No. of patients 184 602 384
NOTE. Boldfaced values represent statistically significant differences
between groups
Abbreviations: iPSA initial prostate-specific antigen, IQR interquartile range
aP value derived from Person’s chi-square test
bP value derived from analysis of variance model
Table 2 Correlation of body mass index with NCCN pre-operative
risk grouping, and post-operative APFs in men undergoing radical
prostatectomy at University of Pennsylvania, 1990–2012
Body mass index (Kg/m2) p-value
≤30 % >30 %
Preoperative Risk group 0.94
Low 521 67 256 33
Intermediate 184 68 86 32
High 78 67 39 33
Postoperative Risk group 0.006
APF = 0 571 70 247 30
APF = 1 114 64 63 36
APF≥ 2 101 58 74 42
Abbreviations: NCCN National Comprehensive Cancer Network, Obese: ≤30 kg/m2;
Non-Obese <30 kg/m2
APFs: adverse pathologic features such as extraprostatic extension, seminal
vesicle invasion, and/or positive surgical margin
Boldfaced values represent statistically significance
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38 %; p = 0.01) and intermediate risk patients (Fig. 1a-b,
29 % vs 47 %; p = 0.02).
After controlling for known preoperative risk factors,
BMI ≥30 kg/m2 was still predictive for the risk of hav-
ing ≥2 APF (OR, 2.58; 95 % CI 1.30 to 5.09; p = 0.006)
using BMI as a categorical variable with BMI <25 kg/m2
as the reference category (Table 3). Although African
American/Black race is associated with elevated BMI,
race was not associated with adverse pathologic out-
comes in the logistic regression models.
Using the Kaplan-Meier survival analysis method, the im-
pact of BMI on freedom from (FFbF) was evaluated. The
mean and median follow up time was 42 and 24 months,
respectively (range 1–245 months). During this time period,
171 patients (15 %) experienced biochemical recurrence.
Higher BMI was significantly associated with worse 7-year
FFbF as follows; BMI-normal: 87 % vs. BMI-Overweight:
76 % vs. BMI-Obese: 61 %; log-rank p = 0.0004; Fig. 2.
Upon stratifying by risk groupings BMI ≥30 kg/m2 had a
significant impact on 7-year FFbF among patients with low
risk (90 % vs. 76 %; log-rank p = 0.004), and a trend towards
worse outcomes for intermediate risk disease (67 % vs.
40 %; log-rank p = 0.08), as shown in Fig. 3.
Using a multivariate Cox proportional hazard model-
ing, the significant predictors of risk for FFbF following
RP were determined, Table 4. After adjusting for the
other preclinical factors BMI ≥30 kg/m2 (HR, 2.56; 95 %
CI 1.24 to 5.29; p = 0.01) remained a predictor of bio-
chemical recurrence.
Discussion
In this current study, further evidence was provided to
suggest that BMI is a strong predictor of APF and
biochemical recurrence following RP as monotherapy,
particularly in patients with low- and intermediate-risk
PCa. Specific groups of PCa patients with localized
disease at presentation may be at increased risk for dis-
ease progression and related PCa-specific mortality from
A
B
Fig. 1 Rate of Gleason score upgrade in a Non-Obese and b Obese men undergoing radical prostatectomy at University of Pennsylvania, 1990-2012.
Abbreviation: GS- Gleason score Gleason score upgrade represent upgrading from either score 6 or 7 to 8 – 10. Obese: ≤30kg/m2; Non-Obese <30kg/m2
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pre-treatment patient phenotype (e.g., obesity.) or post-
treatment adverse pathologic features (e.g., positive surgi-
cal margins, seminal vesicle invasion, extracapsular
extension). Multimodal treatment techniques have been
employed to increase recurrence-free survival among lo-
calized high risk patients [40], and may be useful to treat a
subset of patients with lower risk disease characteristics
but elevated phenotypic risk factors. Although low- and
intermediate risk patients often are treated with monother-
apy, obese men are a patient population with unique dis-
ease features and medical needs that may require a more
aggressive treatment approach including adjuvant RT.
Obesity and PCa outcomes
Previous studies on the association between BMI the
risk of developing PCa have provided mixed results.
Obesity has been shown to increase the risk of poor PCa
outcomes in several studies [2, 41–43]. Recent studies
have analyzed the relation between BMI and PCa risk
stratified by clinical stage and Gleason score at diagno-
sis. These studies consistently showed that elevated BMI
positively correlated with increased risk of higher
Gleason grade or higher stage disease and negatively
correlated with low Gleason grade and stage of disease
[27, 28, 44]. Previous results suggest that obesity is
associated with higher grade tumors, increased risk of
positive surgical margins, higher FFbF rates, and risk for
PCa-specific mortality [1, 2, 33, 45–47]. In multivariate
analyses, obesity also has been associated with significant
tumor upgrading and upstaging among pre-operative
low-risk patients, which increases risk for FFbF among
this patient population [48–52].
However, not all studies support a relationship be-
tween poor PCa outcomes and obesity [53–55]. Often,
studies differ by the number of obese men, sample popu-
lation demographics and study methodology, making it
Table 3 Univariate and multivariate regression models of
factors predicting adverse pathologic outcomes in men
undergoing radical prostatectomy at University of
Pennsylvania, 1990–2012
Univariate analysis OR 95 % CI p value
Age 1 0.98 to 1.03 0.80
Racea
White 1 Reference
African-American/Black 1.21 0.83 to 1.77 0.32
Serum PSA 1.08 1.05 to 1.11 <0.001
Clinical stagea
T1c 1 Reference
T2a 1.05 0.64 to 1.72 0.85
T2b 3.00 1.11 to 8.17 0.03
> T2c 2.58 0.97 to 6.85 0.06
Year of Prostatectomy 0.97 0.94 to 1.00 0.05
Clinical Gleason scorea
≤ 6 1 Reference
7 2.21 1.48 to 3.29 <0.001
≥ 8 5.06 3.03 to 8.43 <0.001
Body mass index, categoricala
< 25 kg/m2 1 Reference
25 kg/m2 to <30 kg/m2 1.48 0.86 to 2.53 0.02
≥ 30 kg/m2 2.20 1.27 to 3.81 0.005
Multivariate analysis
Age 1 0.97 to 1.03 0.74
Racea
White 1 Reference
African-American/Black 0.81 0.50 to 1.32 0.40
Serum PSA 1.12 1.08 to 1.17 <0.001
Clinical stagea
T1c 1 Reference
T2a 1.24 0.72 to 2.14 0.43
T2b 2.28 0.70 to 7.38 0.17
> T2c 1.21 0.37 to 4.03 0.75
Year of Prostatectomy 0.99 0.95 to 1.04 0.69
Clinical Gleason scorea
≤ 6 1 Reference
7 2.01 1.24 to 3.25 0.005
≥ 8 5.97 3.02 to 11.78 <0.001
Table 3 Univariate and multivariate regression models of
factors predicting adverse pathologic outcomes in men
undergoing radical prostatectomy at University of
Pennsylvania, 1990–2012 (Continued)
Body mass index, categoricala
< 25 kg/m2 1 Reference
25 kg/m2 to <30 kg/m2 1.58 0.81 to 3.07 0.18
≥ 30 kg/m2 2.58 1.30 to 5.09 0.006
Abbreviations: PSA prostate-specific antigen, ≥2 adverse pathologic features
as endpoint
aDenotes categorical variables. Body mass index, categorical uses
BMI <25 kg/m2 as reference
Race use White as reference category; “Other” race was dropped from model
due to small numbers
Clinical stage, categorical uses (T1; T2a, T2b; >T2c), with T1c as
reference category
Clinical Gleason score, categorical (6, 7, ≥8); with 6 as reference category
P values derived from a logistic regression model
Boldfaced values represent statistically significance
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difficult to compare across studies. Further complicating
the relationship between obesity and PCa are diagnostic
and treatment obstacles associated with obesity that
make it more likely that cancer will progress and that
treatments will fail on the obese patient due to technical
difficulty rather than biological processes [41, 56–58].
Obese men are less likely than non-obese men to have
abnormal PSA results and undergo biopsy, potentially
effecting timely diagnosis. At the time of biopsy, larger
prostate glands may make it more difficult to detect and
accurately stage cancer [41, 59, 60]. It is also not clear if
the relationship between obesity and treatment failure is
due to aggressive disease biology or to technical limita-
tions. Potency and continence rates after treatment are
similar among weight groups, so technically inferior op-
erations do not account fully for differences in treatment
failure [1]. Pelvic surgery in general is more technically
challenging in obese patients. Obesity has been associ-
ated with 30 % higher odds of capsular incision, a surro-
gate for poor technical operation. However, some
patients receiving poor technique do well after surgery
and others that experienced apparently fine surgical
technique still experience FFbF [61].
Treatment guidelines for low and intermediate risk
patients
Treatment outcomes for patients with low- and inter-
mediate risk disease have been inconsistent in part due to
tumor heterogeneity and inaccuracies in staging [62, 63].
For this reason, low risk patients have recently been
reclassified into very low-risk group (active surveillance
eligible) and low-risk, and there are ongoing discussions
to re-classify intermediate risk patients into low- and
high- intermediate risk groups [64]. Therefore, the ability
to preoperatively identify low or intermediate risk patients
with elevated BMI who are at highest risk of FFbF after
RP as monotherapy will be very useful in guiding upfront
treatment recommendations. Perhaps, these patients may
be best treated with combination therapy (surgery and
RT), or other approaches such as definitive RT with/with-
out hormonal therapy to improve disease control [40].
The current treatment guidelines recommend that pa-
tients with ≥1 APF be offered RT adjuvantly, or as part of a
salvage regimen upon a detectable rise in PSA above
0.2 ng/ml following RP. Adjuvant RT has been shown
in randomized trials to improve PSA-relapse free survival
[19, 22, 65], distant metastasis-free survival and overall sur-
vival [66], compared to observation. Despite these results,
referral patterns for additional RT for these patients remain
very low. In fact less than 20 % of qualifying patients in the
United States actually receive adjuvant RT [67–70] suggest-
ing that many clinicians are reluctant to deliver RT after
RP. In our study, only 2 % of entire cohort had documented
treatment with additional RT. However, this result may be
an underestimation and should be interpreted with caution,
since a good number of patients could undergo RP at
UPHS and then RT locally. RT information for these pa-
tients may not be accurately captured in our database. The
primary reasons for withholding post-RP RT include in-
creased treatment-related toxicity and potentially over
treating patients with RT who may not recurred after RP
[71]. It is estimated that approximately 50 % of patients
with APF will not experience FFbF. Therefore, patients are
offered “active surveillance” post-RP, and RT is only
Fig. 2 Kaplan-Meier curves for FFbF outcomes stratified by body mass index in men undergoing radical prostatectomy at University of
Pennsylvania, 1990–2012. Abbreviations: FFbF- Freedom From biochemical Failure, NCCN- National Comprehensive Cancer Network, BMI- Body
mass index, BMI- Normal: <25kg/m2; BMI - Overweight: ≥25 to <30 kg/m2; BMI- Obese: ≥30kg/m2
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recommended at the earliest signs of PSA failure termed
“early salvage”. However, whether early salvage RT is
equivalent to adjuvant RT is a topic of current investigation
[29]. Unlike RT post-RP, the use of ADT for patients in this
setting is even much less standardized since physicians
often recommend ADT for a number of reasons including
attempting to reduce the prostate size prior to surgery or at
the earliest signs of PSA failure after surgery.
Currently, the decision to recommend definitive radi-
ation treatment for patients with low-intermediate risk
prostate disease is often based on many factors including
patient preference, and/or preexisting comorbid condi-
tions that precludes surgery. However, in patients with
no contraindications for surgery, decision for RT or RP
is largely driven by age, genitourinary toxicity, and the
desire to preserve sexual function [71]. The ability to
identify patients with low-intermediate disease yet at in-
creased risk for APF as well as FFbF will enable clini-
cians to better counsel patients with the appropriate
treatment option that provides the best disease control
with minimal side effects. The existing preclinical factors
used to predict APF and biochemical outcomes are sub-
optimal. In this report elevated BMI was identified as a
preclinical factor that is independently associated with
adverse pathologic outcomes as well as biochemical re-
currence, particularly in patients with low-intermediate
disease or ≤ one adverse pathologic feature. Therefore,
incorporating BMI into the current predictive models
may shows promise in identifying the group of patients
with low-intermediate risk disease who are likely to
experience biochemical recurrence following RP as
monotherapy. These patients could be best treated with
definitive RT with or without hormones thus sparing
them the added toxicity of requiring additional RT after
RP. Further studies are required to develop and validate
the predictive performance of BMI using an independent
patient cohort.
Study limitations
It is important to emphasize that results from this study
cannot be extrapolated to imply that RP is suboptimal
for obese men since not all patients with elevated BMI
experience adverse pathologic outcomes or biochemical
recurrence after surgery. Although elevated BMI was
associated with increased positive surgical margins,
BMI still was associated with adverse pathologic out-
comes after adjusting for margin status. This suggests
that poorer surgical outcomes did not account for worse
pathologic outcomes in obese men. Therefore, patients
with elevated BMI may harbor a biologically more
aggressive PCa. Limitations to this study were that
important measures of obesity, such as waist-to-hip
ratio and percent lean body fat were unavailable. Infor-
mation on the biologic factors that may contribute to
the effect of elevated BMI on disease aggressiveness and
treatment outcomes could not be evaluated since blood
biosamples were not obtained at the time of surgery.
Furthermore, the median follow-up for the study cohort
was relatively short.
A
B
C
Fig. 3 Kaplan-Meier curves for FFbF outcomes by BMI stratified by
NCCN risk groups in men undergoing radical prostatectomy at University
of Pennsylvania, 1990–2012. Abbreviations: FFbF- Freedom From
biochemical Failure, NCCN- National Comprehensive Cancer Network,
BMI- Body mass index, Non-Obese: <30kg/m2; Obese: ≥30kg/m2 . NCCN
risk groupings: Panel A) Low risk; B) Intermediate risk; C) High risk
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Conclusions
Elevated BMI is independently associated with APF, par-
ticularly in patients with low-intermediate risk disease.
BMI may be useful as a predictive tool to augment the
performance of the known preclinical factors in predict-
ing adverse pathologic outcome and the use of adjuvant
RT post-RP. Therefore, BMI should be considered in
clinical decision-making for appropriate treatment
recommendation for patients with low-intermediate
risk PCa.
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Table 4 Univariate and multivariate regression models of
pre-operative factors predicting FFbF in men undergoing
radical prostatectomy at University of Pennsylvania,
1990–2012
Univariate analysis HR 95 % CI p value
Age 1 0.98 to 1.03 0.80
Racea
White 1 Reference
African-American/Black 1.28 0.92 to 1.78 0.15
Serum PSA 1.03 1.02 to 1.04 <0.001
Clinical stagea
T1c 1 Reference
T2a 1.57 1.01 to 2.45 0.04
T2b 2.70 1.24 to 5.88 0.01
> T2c 0.72 0.18 to 2.92 0.64
Year of Prostatectomy 1.01 0.98 to 1.05 0.55
Clinical Gleason scorea
≤ 6 1 Reference
7 2.34 1.61 to 3.39 <0.001
≥ 8 4.63 3.12 to 6.87 <0.001
Body mass index, categoricala
< 25 kg/m2 1 Reference
25 kg/m2 to <30 kg/m2 1.99 1.13 to 3.50 0.02
≥ 30 kg/m2 2.89 1.62 to 5.16 <0.001
Multivariate analysis
Age 0.99 0.96 to 1.01 0.31
Racea
White 1 Reference
African-American/Black 0.67 0.43 to 1.04 0.07
Serum PSA 1.02 1.01 to 1.03 <0.001
Clinical stagea
T1c 1 Reference
T2a 1.75 1.11 to 2.75 0.015
T2b 0.91 0.36 to 2.30 0.84
> T2c 0.27 0.06 to 1.14 0.07
Year of Prostatectomy 1.02 0.99 to 1.06 0.20
Clinical Gleason scorea
≤ 6 1 Reference
7 2.69 1.71 to 4.24 <0.001
≥ 8 7.27 4.26 to 12.42 <0.001
Table 4 Univariate and multivariate regression models of
pre-operative factors predicting FFbF in men undergoing
radical prostatectomy at University of Pennsylvania,
1990–2012 (Continued)
Body mass index, categoricala
< 25 kg/m2 1 Reference
25 kg/m2 to <30 kg/m2 1.97 0.97 to 4.01 0.06
≥ 30 kg/m2 2.56 1.24 to 5.29 0.01
Abbreviations: PSA prostate-specific antigen, FFbF freedom from
biochemical failure
aDenotes categorical variables. Body mass index, categorical uses BMI <25 kg/m2
as reference
Race use White as reference category; “Other” race was dropped from model
due to small numbers. Clinical stage, categorical uses (T1; T2a, T2b; >T2c), with
T1c as reference category
Clinical Gleason score, categorical (6, 7, ≥8); with 6 as reference category
P values derived from a logistic regression model
Boldfaced values represent statistically significance
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